Report: Drug companies profit from dual eligibles

Share this article:

The pharmaceutical industry is experiencing a "windfall" from Medicare's coverage of dual eligibles in the Part D drug program, according to a news report.

Companies are benefiting from the transfer of drug coverage for dual eligible beneficiaries from state Medicaid programs to the Medicare prescription drug benefit. The new benefit exempts Part D drugs from "best price" price rebates. Before the implementation of the drug benefit, drug makers were required to give these rebates to state Medicaid programs.

Without the rebates, the annual cost to states for drugs for beneficiaries who are eligible for both Medicare and Medicaid would have been about 25% higher, said Stephen Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota.
Share this article:

More in News

Double homicide at Houston nursing home; victims' roommate arrested

Double homicide at Houston nursing home; victims' roommate ...

A double murder occurred late Tuesday night in a Houston nursing home room shared by four men, according to local authorities. Police arrested Guillermo Correa on suspicion of beating two ...

$2 million HIPAA settlement highlights mobile device risks facing healthcare providers

Laptops and other mobile devices containing personal health information have been stolen from long-term care ombudsman programs and other healthcare organizations, including from Concentra Health Services and QCA Health Plan Inc. Now, Concentra and QCA have agreed to legal settlements totaling nearly $2 million, federal ...

Long-term care nurses often 'scramble' to get family members' blessing for palliative ...

Nursing home residents might not transition to full palliative care until they are very near death, at which point nurses and family members act in a state of crisis, suggests recently published research out of Canada.